New Drug Brings Hope for Liver Cancer Patients (China)
This article was originally published in PharmAsia News
Executive Summary
An ongoing study conducted by HKU Li Ka Shing Faculty of Medicine and Queen Mary Hospital in Hong Kong has used Sorafenib on 50 advanced liver cancer patients. The drug is developed by German pharmacy group Bayer AG. In the first trial of Sorafenib on 16 Hong Kong patients, conditions of 13 and 25 percent have improved and stabilized respectively after their tumor growth was reassessed by CT scan after three months. A new drug that targets molecular pathways of cancer, Sorafenib hinders both tumor cell proliferation and a protein known as vascular endothelial growth factor. "Without using the drug, most of these patients could have died within three months after diagnosed with advanced liver cancer," says Professor Ronnie Poon Tung-ping of the Department of Surgery, HKU Li Ka Shing Faculty of Medicine. "Unlike other cancers such as breast cancer, there is no systemic therapy for liver cancer and it is resistant to conventional chemotherapy," he adds. "Compared to conventional chemotherapy, the drug is safe and has simpler curing process." (Click here for more
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.